The Fusion Protein Engineering and Developability Summit is the definitive event catering to drug developers with novel fusion protein pipelines - it is a conference not to be missed! With rapid development in novel fusion protein pipelines fuelling the demand for practical, effective engineering techniques to accelerate developable drugs into the clinic, you simply can't miss out on this highly anticipated event. With leading experts from Roche, Merck, Bristol Myers Squibb, Abbvie and many more, this is a unique opportunity to connect with other drug developers, share innovative ideas and strategies, and gain valuable insights on cutting edge fusion applications.

Read on fusion-protein.com

The Fusion Protein Engineering and Developability Summit is the definitive event catering to drug developers with novel fusion protein pipelines - it is a conference not to be missed! With rapid development in novel fusion protein pipelines fuelling the demand for practical, effective engineering techniques to accelerate developable drugs into the clinic, you simply can't miss out on this highly anticipated event. With leading experts from Roche, Merck, Bristol Myers Squibb, Abbvie and many more, this is a unique opportunity to connect with other drug developers, share innovative ideas and strategies, and gain valuable insights on cutting edge fusion application. With 24+ speakers, 3 hands-on workshops, and 2 days of packed data-driven case studies, this is set to be the definitive event of the year and you cannot afford to miss it!

Read on go.evvnt.com

Prepare to be captivated by the Fusion Protein Engineering and Developability Summit, the ultimate event tailored to drug developers with ground-breaking fusion protein pipelines. This conference is an absolute game-changer that should be at the top of your priority list!

As the demand for practical and effective engineering techniques to expedite the development of viable drugs into clinical applications skyrockets, this highly anticipated summit offers an unrivalled opportunity. Join forces with esteemed experts from industry giants like Roche, Merck, Bristol Myers Squibb, Abbvie, and an array of other distinguished names. Seize this unique occasion to connect with fellow drug developers, exchange innovative ideas and strategies, and gain invaluable insights into cutting-edge fusion applications.

Read on go.evvnt.com

There is a vast number of ADCs that never make it to the clinic let alone to market, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity, their translatability into the clinic, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures.

The first-of-its-kind ADC Toxicity Summit will allow companies developing ADCs to overcome toxicological related challenges, by hearing case-study-led presentations on approved ADCs, including ImmunoGen's Mirvetuximab Soravtansine, as well as important scientific and strategic discussions. Designed to provide you with the toolkit to design and deliver more tolerable ADCs to patients without lowering efficacy this is your exclusive opportunity to join peers with expertise in toxicology, safety, and pathology.

Read on adc-toxicity.com

The AACC Annual Scientific Meeting & Clinical Lab Expo is an opportunity to connect with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine. With more than 250 educational opportunities in the form of lectures, plenary sessions, scientific sessions, and roundtable sessions, it's an educational experience that meets the need to stay ahead of changes in the field.

Read on cgm.com

With UPSIDE Foods recently receiving 'no further questions' from the FDA, the race to advance cultivated meat and seafood from petri to plate is on! As the field turns their focus to optimizing their bioprocess and refining cost-effective scale-up approaches, don't miss your opportunity to hear detailed case-studies to advance your development infrastructure and bring to market cost-effective and scalable products.

At the only business-to-business forum dedicated exclusively to accelerating cultivated meat and seafood products to market, join BlueNalu, Fork and Good, Umami Meats, the Good Food Institute, the FDA and USDA and many more industry leaders to benchmark solutions for affordable bioprocessing.

Join to discuss the most prevalent issues preventing cultivated meat and seafood products from reaching the market. With sessions dedicated specifically to refining food-grade economical media and cell-development; navigating the investors minefield; building bioprocessing infrastructure and gaining regulatory insights to streamline the approval process, the Industrializing Cultivated Meat and Seafood Summit is your one-stop-shop for achieving regulatory approval and progressing your product to shelves and tabletops across the globe.

Read on industrializingcultivatedmeats.com

The gamma delta T wave is cresting as industry leaders such as Adicet Bio, Leucid, Century, Imcheck, IN8bio, Sanofi and Takeda race to demonstrate the clinical benefit and efficacy of gamma delta T therapies, spanning cell-based to antibody and small molecule approaches. Spurred by early evidence of clinical efficacy, the industry returns in 2023 armed with more subset-specific and clinical mechanistic understanding, snowballing investment, and growing expert end-to-end teams. This is the prime time to gather with the gamma delta T therapies industry to contrast subsets, characterize mechanisms of action, and optimize product design to develop globally accessible, solid tumor therapies.

Ensure you don't miss this comprehensive, forward-facing summit, bringing together 150+ gamma delta T pioneers with 40+ industry-leading speakers including Adrian Hayday, Bruno Silva-Santos and Larry Lamb, collaborating and brainstorming approaches to tackle the most pressing hurdles in this burgeoning field.

Don't miss your chance to to enhance process development, overcome with expert learnings from the 4th Gamma Delta T Therapies Summit.

 Read on gamma-delta-t-therapies.com

Whilst still in infancy, the rise of multispecific drugs that drive induced proximity between otherwise disparate biological targets is shifting the drug discovery paradigm towards therapeutic interventions for previously undrugged, or hard-to-drug targets with clinical value.

As the only industry dedicated forum to radically advance heterobifunctional drug discovery, the 3rd Induced Proximity-Based Drug Discovery Summit is set to unite 50+ key leaders in biopharma and academia who are eager to take a deeper dive into early drug discovery, protein interactions and the novel modalities that are emerging in the space.

Hear from 22+ expert speakers across 3 days of data-driven presentations, technical workshops, and panel discussions to push the therapeutic limits of the field. This is an exclusive opportunity to discover better binders, design efficient heterobifunctionals and accelerate proof of concept gain at the only summit focused on helping you progress your induced proximity pipelines from conception to clinic.

Read on induced-proximity-summit.com/

It's time for medical meeting professionals to take a seat at the leadership table.
You asked for it, and we delivered. The first industry event for medical meeting professionals that elevates the conversation beyond logistics and answers the questions:
- How can you be more strategic?
- Can you leverage AI and other applications to free up the bandwidth needed to apply strategy?
- Has meeting planning at life science companies evolved into vendor management?
- Is there a way to better optimize resources with a balance of full-time and contract workers?
- How is it the duty of meeting professionals to support corporate DE and I policies through intentional site selection?

Read on go.evvnt.com

Join us as we unite 100+ key stakeholders across the space from large pharma, biotech, academia, physicians, nuclear physicists, cyclotron providers, manufacturers, linker developers, TRP-experienced CROs and many more, to bring the targeted radiotherapies to the forefront of cancer treatment.

Take this unique opportunity to connect with all the key players in the targeted radiopharmaceuticals space as they learn the ins-and-outs of the progress, gain a deep and holistic insight of the current state-of-play in the US TRP landscape, and challenges the leading experts in the space are experiencing.

Read on targeted-radiopharma-us.com